ONCY oncolyticsbiotech.com: Enterprise Value to EBITDA Ratio

Brandmark of Oncolytics Biotech Inc. (ONCY)

This trading chart helps assess the business value of Oncolytics Biotech Inc. (ONCY), where the EV/EBITDA multiple stands at 0.00. Oncolytics Biotech Inc. (ONCY) leverages significant pricing power driven by its unique reovirus that selectively targets tumors. Management is focused on implementing innovative therapy standards and securing partners. An extensive patent portfolio and global alliances protect the developer from competitive pricing pressure.

ONCY Oncolytics Biotech, Inc.: Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/12/2026

Metric breakdowns and analytics for oncolyticsbiotech.com (ONCY)

- stock price and consensus target price:
Stock Quotes Oncolytics Biotech|ONCY - Average Forecast Price
- company stock capitalization data:
Market Valuation Oncolytics Biotech Inc.|ONCY - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share Oncolytics Biotech|ONCY - Net Asset Value|Market Value to Book Value Ratio oncolyticsbiotech.com|ONCY - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Oncolytics Biotech Inc.|ONCY - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Oncolytics Biotech|ONCY - Company Cumulative Indebtedness|Debts to Book Capitalization Oncolytics Biotech Inc.|ONCY - Long-Term Liabilities|Company Short-Term Debt Oncolytics Biotech|Quick Liquidity oncolyticsbiotech.com
- business earnings and investment ratios data:
ONCY - Final Profit|Expected Profit Oncolytics Biotech Inc.|ONCY - Price to Earnings Ratio|Future Price to Earnings Oncolytics Biotech|ONCY - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncolytics Biotech Inc.|ONCY - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Oncolytics Biotech|ONCY - Earnings per share for the last 12 months|Quarterly EPS earnings growth oncolyticsbiotech.com|ONCY - Net earnings per share growth this year|Net earnings per share growth forecast for next year Oncolytics Biotech Inc.
General company analysis:Oncolytics ONCY
Product sample of Oncolytics Biotech, Inc.

The operational efficiency of Oncolytics Biotech Inc. (ONCY) is reflected in its current EV/EBITDA multiple. This indicator compares the total enterprise value, including net debt, with earnings before interest, taxes, depreciation, and amortization. This methodology allows for an assessment of the real value of assets, stripped of the influence of financial leverage. For a biotechnology company with strong patent protection, this ratio confirms the investment attractiveness of its fundamental base.

Direct competitors

Geron Corp. - Enterprise Value to EBITDA Ratio|Nanobiotix Group (NBTX) - Company Value to EBITDA|BCYC: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CTMX (cytomx.com)|perspectivetherapeutics.com (CATX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GNLX (Genelux)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Partners AG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSTA|EV/EBITDA Multiple MBRX|EV/EBITDA Multiple galeratx.com (GRTX)|Molecular Templates, Inc. - Enterprise Value to EBITDA Ratio